Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05093296
Other study ID # CIMH ON-ICE 21
Secondary ID
Status Completed
Phase Phase 2/Phase 3
First received
Last updated
Start date December 2, 2021
Est. completion date September 27, 2023

Study information

Verified date March 2024
Source Central Institute of Mental Health, Mannheim
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Alcohol use disorder (AUD) is a chronic relapsing disorder. Alcohol craving, a hallmark symptom of AUD that drives relapse in patients, is only insufficiently treated by existing medication. One promising new compound is Oxytocin (OXY), which showed beneficial effects on alcohol craving in preliminary clinical studies. Additionally, OXY seems to enhance effects of established medication, specifically Naltrexone (NTX), an opioid-antagonist which is approved for AUD treatment via positive synergism on neurotransmitter levels. The proposed two-armed, 1:1 randomized, double-blind, parallel group trial seeks to test the putative synergistic effects of combined intranasal OXY spray (24 IU) + oral NTX (50mg) against Placebo spray + oral NTX (50mg) on alcohol craving (primary outcome) in male and female patients with AUD that suffer from high alcohol craving, within the framework of a validated alcohol cue-and stress-exposure task (i.e. a combined Trier Stress Test and alcohol cue-exposure) that was established for screening new medications in AUD and determine their effects on craving and relapse risk. Treatment effects on additional neurobiological and biochemical markers of craving that show strong associations to individual relapse risk, will serve as secondary outcomes. Collection and analysis of follow-up data (90 days) will be performed to determine whether treatment effects relate to patient outcome. The clinical trial period for an individual participant consists of a screening visit (visit 1), a baseline visit (visit 2) and two treatment visits (visits 3 and 4)(all within equal or less than ten days) followed by a 90 days (+/- 7 days) follow-up phase with two visits (visits 5 and 6) at day 30 (± 7 days) and day 90 (± 7 days). Visits 1 to 4 will be conducted while participants are undergoing standard in-patient treatment at the Department of Addictive Behavior and Addiction medicine at the Central Institute of Mental Health (CIMH) in Mannheim, Germany, for the medical condition under investigation.


Recruitment information / eligibility

Status Completed
Enrollment 62
Est. completion date September 27, 2023
Est. primary completion date July 15, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria: - Age between 18 and 70 years - Patients meeting the diagnosis of an alcohol dependence according to the Internation Clasification of Diseases 10th revision (ICD10) - Patients with at least moderate craving, i.e. either >=15 points on the Alcohol Urge Questionnaire (AUQ, range 8 to 56 points) craving scale or increase in AUQ scores by >= 50% after exposure to visual alcohol cues (i.e. minimum increase of >=4 points after cue exposure) - Ability of the individual to understand the character and the individual consequences of the clinical trial - Written informed consent (must be available before enrollment in the study) - Consent to random assignment - For women with childbearing potential, use of a highly effective birth control method until 24 hours after Visit 4 and negative pregnancy test Exclusion Criteria: - Subjects presenting with any of the following criteria will not be included in the clinical trial: Current psychotic or bipolar disorder or current severe depressive episode with suicidal ideations - Current treatment with any of the following substances: Any investigational medicinal product, Opioid-containing Analgesics, Anorexics, Anticonvulsants, Opioid-containing Antidiarrheal Agents, Antineoplastics, Antipsychotics (exception: episodic use of melperone, pipamperone and quetiapine are allowed), Antidepressants (exception: allowed, when being taken in stable dose for a minimum of 14 days prior to enrolment and/or doxepin in low doses [max. 75mg daily]), Opioid-containing Cough/cold agents, systemic Steroids - Positive drug screening (amphetamines/ecstasy, opiates, cocaine, barbiturates) - Pregnancy, lactation or breastfeeding - Current severe somatic comorbidities: liver cirrhosis [CHILD B or C] or impaired renal function [glomerular filtration rate (GFR)<15ml/Min] [each determined by physical examination and/or laboratory testing], severe heart insufficiency [determined by assessment of medical history], pre-existing epilepsy [determined by assessment of medical history], long-QT syndrome or cardial arrhythmia [determined by ECG] - History of hypersensitivity to the investigational medicinal product Oxytocin (Syntocinon®) and/or Naltrexone (trade names: Adepend, Naltrexon-Hcl neuraxpharm, Naltrexonhydrochlorid Accord) or to any drug with similar chemical structure or to any excipient present in the pharmaceutical form of the investigational medicinal product Oxytocin (Syntocinon®) and/or Naltrexone - Participation in other clinical trials or observation period of competing clinical trials, respectively. - Acute suicidal tendency or acute endangerment of self and others

Study Design


Intervention

Drug:
Oxytocin nasal spray
24 I.U. Oxytocin nasal Spray will be administered twice on two separate trial days.
Naltrexone Pill
All participants will receive 50mg Naltrexone daily as oral tablet throughout the study
Placebo
Placebo nasal spray (same composition as the verum oxytocin spray except for the active ingredient oxytocin)

Locations

Country Name City State
Germany Central Institute of Mental Health Mannheim

Sponsors (4)

Lead Sponsor Collaborator
Central Institute of Mental Health, Mannheim German Federal Ministry of Education and Research, Heidelberg University - Coordination Centre for Clinical Trials (KKS) of Heidelberg University, Heidelberg University - Institute of Medical Biometry (IMBI)

Country where clinical trial is conducted

Germany, 

Outcome

Type Measure Description Time frame Safety issue
Primary Alcohol Urge Questionnaire (AUQ) Subjective Alcohol Craving will be assessed at separate time points before and after Oxytocin Administration using the AUQ 60 minutes after oxytocin/placebo application and directly after the combined stress- and cue-exposure will serve as primary outcome measure at Visit 3
Secondary Alcohol Urge Questionnaire (AUQ) Subjective Alcohol Craving will be assessed at separate time points before and after Oxytocin Administration using the AUQ 35 minutes after oxytocin/placebo application at Visit 3
Secondary Alcohol Urge Questionnaire (AUQ) Subjective Alcohol Craving will be assessed at separate time points before and after Oxytocin Administration using the AUQ 70 minutes after oxytocin/placebo application at Visit 3
Secondary Alcohol Urge Questionnaire (AUQ) Subjective Alcohol Craving will be assessed at separate time points before and after Oxytocin Administration using the AUQ 80 minutes after oxytocin/placebo application at Visit 3
Secondary Alcohol Urge Questionnaire (AUQ) Subjective Alcohol Craving will be assessed at separate time points before and after Oxytocin Administration using the AUQ 90 minutes after oxytocin/placebo application at Visit 3
Secondary Alcohol Urge Questionnaire (AUQ) Subjective Alcohol Craving will be assessed at separate time points before and after Oxytocin Administration using the AUQ 85 minutes after oxytocin/placebo application, i.e. directly fMRI session at Visit 4
Secondary Primary Appraisal secondary Appraisal Scale (PASA) Perceived stress will be assessed using the Primary Appraisal secondary Appraisal Scale (PASA) at separate time points before and after Oxytocin Administration using the AUQ at Visit 3 and Visit 4 35 minutes after oxytocin/placebo application at Visit 3
Secondary Primary Appraisal secondary Appraisal Scale (PASA) Perceived stress will be assessed using the Primary Appraisal secondary Appraisal Scale (PASA) at separate time points before and after Oxytocin Administration using the AUQ at Visit 3 and Visit 4 60 minutes after oxytocin/placebo application at Visit 3
Secondary Primary Appraisal secondary Appraisal Scale (PASA) Perceived stress will be assessed using the Primary Appraisal secondary Appraisal Scale (PASA) at separate time points before and after Oxytocin Administration using the AUQ at Visit 3 and Visit 4 90 minutes after oxytocin/placebo application at Visit 3
Secondary Primary Appraisal secondary Appraisal Scale (PASA) Perceived stress will be assessed using the Primary Appraisal secondary Appraisal Scale (PASA) at separate time points before and after Oxytocin Administration using the AUQ at Visit 3 and Visit 4 85 minutes after oxytocin/placebo application, i.e. directly fMRI session at Visit 4
Secondary Positive and Negative Affect Schedule (PANAS) Positive and Negative Affect will be assessed using the Positive and Negative Affect Schedule (PANAS) at separate time points before and after Oxytocin Administration using the AUQ at Visit 3 and Visit 4 60 minutes after oxytocin/placebo application at Visit 3
Secondary Positive and Negative Affect Schedule (PANAS) Positive and Negative Affect will be assessed using the Positive and Negative Affect Schedule (PANAS) at separate time points before and after Oxytocin Administration using the AUQ at Visit 3 and Visit 4 85 minutes after oxytocin/placebo application, i.e. directly fMRI session at Visit 4
Secondary Cortisol Cortisol plasma levels will be determined using validated Enzyme-linked Immunosorbent Assay (ELISA) methods by the central laboratory at visit 3 after Oxytocin/Placebo administration 65 minutes after oxytocin/placebo application at Visit 3
Secondary Oxytocin Oxytocin plasma levels will be determined using validated ELISA methods by the central laboratory at visit 3 after Oxytocin/Placebo administration 30 minutes after oxytocin/placebo application at Visit 3
Secondary Oxytocin Oxytocin plasma levels will be determined using validated ELISA methods by the central laboratory at visit 3 after Oxytocin/Placebo administration 65 minutes after oxytocin/placebo application at Visit 3
Secondary Alcohol Cue-induced neural brain activation during an Alcohol cue-reactivity functional magnetic resonance imaging (fMRI) task Neural brain activation in the mesocorticolimbic system (whole-brain and Region-of-Interest Analyses (ROIs): ventral striatum, dorsal striatum, insula), measured using the blood oxygenated level dependent (BOLD) response, during presentation of alcohol cues will serve as secondary outcome During fMRI session at Visit 4, i.e. 40 to 85 minutes after Oxytocin/Placebo administration
Secondary Neural Activation during a natural reward cue-reactivity fMRI task Neural brain activation in the mesocorticolimbic system (whole-brain and ROIs: ventral striatum, dorsal striatum, insula), measured using the blood oxygenated level dependent (BOLD) response during the presentation of natural reward cues will serve as secondary outcome During fMRI session at Visit 4, i.e. 40 to 85 minutes after Oxytocin/Placebo administration
Secondary Neural Activation during a Face-matching fMRI task Neural brain activation in the mesocorticolimbic system (whole-brain and ROIs: ventral striatum, dorsal striatum, insula, amygdala), measured using the blood oxygenated level dependent (BOLD) response during the presentation of emotional faces and neutral shapes will serve as secondary outcome During fMRI session at Visit 4, i.e. 40 to 85 minutes after Oxytocin/Placebo administration
Secondary Neural Activation during a Stop Signal fMRI Task Neural brain activation in the mesocorticolimbic system (whole-brain and ROIs: ventral striatum, dorsal striatum, insula, dlPFC), measured using the blood oxygenated level dependent (BOLD) response during a stop signal fMRI task will serve as secondary outcome During fMRI session at Visit 4, i.e. 40 to 85 minutes after Oxytocin/Placebo administration
Secondary Adverse Events (AEs)/Serious Adverse Events (SAEs) and Discontinuation rate Rate of adverse events, serious adverse events and rate of discontinuation of the study due to an adverse event During Study Visits 1 to 6, including the 90 day (±7 day) follow-up period
Secondary Subjective quality of life index Quality of life will be assessed using the WHO-QOL-BREF scores At Visit 5, i.e. 30 days (+/- 7 days) after Visit 3
Secondary Subjective quality of life index Quality of life will be assessed using the World Health Organization (WHO) Quality of life assessment (WHO-QOL-BREF) scores At Visit 6, i.e. 90 days (+/- 7 days) after Visit 3
Secondary Time to relapse during the follow-up period of 90 days (+/- 7 days) Time from randomization to relapse to alcohol use (in days) During 90-day (± 7 days) Follow-up
Secondary Cumulative alcohol consumption during the follow-up period of 90 days (+/- 7 days) Self-reported cumulative alcohol use (in gram) During 90-day (± 7 days) Follow-up
Secondary Percent heavy drinking days during the follow-up period of 90 days (+/- 7 days) Self-reported percent heavy drinking days (in %) During 90-day (± 7 days) Follow-up
See also
  Status Clinical Trial Phase
Recruiting NCT04788004 - Long-term Recovery: Longitudinal Study of Neuro-behavioral Markers of Recovery and Precipitants of Relapse
Recruiting NCT05684094 - Mechanisms of Risky Alcohol Use in Young Adults: Linking Sleep to Reward- and Stress-Related Brain Function N/A
Completed NCT03406039 - Testing the Efficacy of an Online Integrated Treatment for Comorbid Alcohol Misuse and Emotional Problems N/A
Completed NCT03573167 - Mobile Phone-Based Motivational Interviewing in Kenya N/A
Completed NCT04817410 - ED Initiated Oral Naltrexone for AUD Phase 1
Active, not recruiting NCT04267692 - Harm Reduction Talking Circles for American Indians and Alaska Natives With Alcohol Use Disorders N/A
Completed NCT03872128 - The Role of Neuroactive Steroids in Stress, Alcohol Craving and Alcohol Use in Alcohol Use Disorders Phase 1
Completed NCT02989662 - INIA Stress and Chronic Alcohol Interactions: Glucocorticoid Antagonists in Heavy Drinkers Phase 1/Phase 2
Recruiting NCT06030154 - Amplification of Positivity for Alcohol Use N/A
Active, not recruiting NCT05419128 - Family-focused vs. Drinker-focused Smartphone Interventions to Reduce Drinking-related Consequences of COVID-19 N/A
Completed NCT04564807 - Testing an Online Insomnia Intervention N/A
Completed NCT04284813 - Families With Substance Use and Psychosis: A Pilot Study N/A
Completed NCT04203966 - Mental Health and Well-being of People Who Seek Help From Their Member of Parliament
Recruiting NCT05861843 - Craving Assessment in Patients With Alcohol Use Disorder Using Virtual Reality Exposure
Terminated NCT04404712 - FAAH Availability in Psychiatric Disorders: A PET Study Early Phase 1
Enrolling by invitation NCT04128761 - Decreasing the Temporal Window in Individuals With Alcohol Use Disorder N/A
Not yet recruiting NCT06163651 - Evaluating a One-Year Version of the Parent-Child Assistance Program N/A
Not yet recruiting NCT06444243 - Psilocybin-assisted Therapy for Alcohol Use Disorder Phase 2
Not yet recruiting NCT06337721 - Preventing Alcohol Use Disorders and Alcohol-Related Harms in Pacific Islander Young Adults N/A
Enrolling by invitation NCT02544581 - Preliminary Analysis of the Soberlink Alcohol Breath Analyzer System's (SABA) Clinical Utility During Aftercare N/A